Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities maintained a Buy rating on the stock and has a €123.00 price target.
Graham Parry has given his Buy rating due to a combination of factors, primarily focusing on Sanofi’s strong financial performance and promising pipeline developments. The company’s first-quarter earnings per share exceeded expectations by 5%, and sales were 3% above consensus, demonstrating robust growth. Additionally, Sanofi’s key products, such as Dupixent and Beyfortus, have shown impressive sales momentum, contributing to the company’s overall positive outlook.
Furthermore, Parry highlights the undervaluation of Sanofi’s growth potential, with a projected earnings per share increase of 19% year-over-year, which is ahead of consensus estimates. The promising pipeline, including significant developments in treatments for COPD and other conditions, supports the expectation of continued positive earnings momentum. Despite some foreign exchange headwinds, the company’s financial guidance remains conservative, suggesting room for potential upside, which reinforces the Buy rating.
According to TipRanks, Parry is ranked #2756 out of 9371 analysts.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a €127.00 price target.